Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 108

1.

Mastocytosis: advances in diagnosis and treatment.

Hungness SI, Akin C.

Curr Allergy Asthma Rep. 2007 Jul;7(4):248-54. Review.

PMID:
17547845
2.

Imatinib mesylate in the treatment of systemic mastocytosis: a phase II trial.

Droogendijk HJ, Kluin-Nelemans HJ, van Doormaal JJ, Oranje AP, van de Loosdrecht AA, van Daele PL.

Cancer. 2006 Jul 15;107(2):345-51.

3.

Recent advances in the understanding of mastocytosis: the role of KIT mutations.

Orfao A, Garcia-Montero AC, Sanchez L, Escribano L; REMA.

Br J Haematol. 2007 Jul;138(1):12-30. Review.

PMID:
17555444
4.

[Therapeutically relevant mutations in the receptor tyrosine kinase KIT in mastocytosis].

Sotlar K.

Verh Dtsch Ges Pathol. 2007;91:169-76. German.

PMID:
18314612
5.

Tyrosine kinase inhibitors in the treatment of systemic mastocytosis.

Ustun C, DeRemer DL, Akin C.

Leuk Res. 2011 Sep;35(9):1143-52. doi: 10.1016/j.leukres.2011.05.006. Epub 2011 Jun 8. Review.

PMID:
21641642
6.

In vitro and in vivo growth-inhibitory effects of cladribine on neoplastic mast cells exhibiting the imatinib-resistant KIT mutation D816V.

Böhm A, Sonneck K, Gleixner KV, Schuch K, Pickl WF, Blatt K, Peter B, Herrmann H, Schernthaner GH, Pehamberger H, Rabitsch W, Sperr WR, Valent P.

Exp Hematol. 2010 Sep;38(9):744-55. doi: 10.1016/j.exphem.2010.05.006. Epub 2010 May 27.

PMID:
20553795
7.

Ponatinib induces apoptosis in imatinib-resistant human mast cells by dephosphorylating mutant D816V KIT and silencing β-catenin signaling.

Jin B, Ding K, Pan J.

Mol Cancer Ther. 2014 May;13(5):1217-30. doi: 10.1158/1535-7163.MCT-13-0397. Epub 2014 Feb 19.

8.

A novel form of mastocytosis associated with a transmembrane c-kit mutation and response to imatinib.

Akin C, Fumo G, Yavuz AS, Lipsky PE, Neckers L, Metcalfe DD.

Blood. 2004 Apr 15;103(8):3222-5. Epub 2003 Dec 24.

9.

KIT and mastocytosis.

Lim KH, Pardanani A, Tefferi A.

Acta Haematol. 2008;119(4):194-8. doi: 10.1159/000140630. Epub 2008 Jun 20. Review.

PMID:
18566536
10.

Growth-inhibitory effects of four tyrosine kinase inhibitors on neoplastic feline mast cells exhibiting a Kit exon 8 ITD mutation.

Hadzijusufovic E, Peter B, Rebuzzi L, Baumgartner C, Gleixner KV, Gruze A, Thaiwong T, Pickl WF, Yuzbasiyan-Gurkan V, Willmann M, Valent P.

Vet Immunol Immunopathol. 2009 Dec 15;132(2-4):243-50. doi: 10.1016/j.vetimm.2009.05.007. Epub 2009 May 18.

PMID:
19505729
11.

Molecular changes associated with the development of resistance to imatinib in an imatinib-sensitive canine neoplastic mast cell line carrying a KIT c.1523A>T mutation.

Kobayashi M, Kuroki S, Tanaka Y, Moriya Y, Kozutumi Y, Uehara Y, Ono K, Tamura K, Washizu T, Bonkobara M.

Eur J Haematol. 2015 Dec;95(6):524-31. doi: 10.1111/ejh.12526. Epub 2015 Mar 13.

PMID:
25684098
12.

Molecular defects in mastocytosis: KIT and beyond KIT.

Bibi S, Langenfeld F, Jeanningros S, Brenet F, Soucie E, Hermine O, Damaj G, Dubreuil P, Arock M.

Immunol Allergy Clin North Am. 2014 May;34(2):239-62. doi: 10.1016/j.iac.2014.01.009.

PMID:
24745672
13.

EXEL-0862, a novel tyrosine kinase inhibitor, induces apoptosis in vitro and ex vivo in human mast cells expressing the KIT D816V mutation.

Pan J, Quintás-Cardama A, Kantarjian HM, Akin C, Manshouri T, Lamb P, Cortes JE, Tefferi A, Giles FJ, Verstovsek S.

Blood. 2007 Jan 1;109(1):315-22. Epub 2006 Aug 15.

14.

The Kit-activating mutation D816V enhances stem cell factor--dependent chemotaxis.

Taylor ML, Dastych J, Sehgal D, Sundstrom M, Nilsson G, Akin C, Mage RG, Metcalfe DD.

Blood. 2001 Aug 15;98(4):1195-9.

15.

Allele-specific polymerase chain reaction for the imatinib-resistant KIT D816V and D816F mutations in mastocytosis and acute myelogenous leukemia.

Corless CL, Harrell P, Lacouture M, Bainbridge T, Le C, Gatter K, White C Jr, Granter S, Heinrich MC.

J Mol Diagn. 2006 Nov;8(5):604-12.

16.

Systemic mastocytosis: current classification and novel therapeutic options.

Barbie DA, Deangelo DJ.

Clin Adv Hematol Oncol. 2006 Oct;4(10):768-75. Review.

PMID:
17099633
17.

Resistance to c-KIT kinase inhibitors conferred by V654A mutation.

Roberts KG, Odell AF, Byrnes EM, Baleato RM, Griffith R, Lyons AB, Ashman LK.

Mol Cancer Ther. 2007 Mar;6(3):1159-66.

19.

Novel thiazole amine class tyrosine kinase inhibitors induce apoptosis in human mast cells expressing D816V KIT mutation.

Jin Y, Ding K, Wang D, Shen M, Pan J.

Cancer Lett. 2014 Oct 10;353(1):115-23. doi: 10.1016/j.canlet.2014.07.017. Epub 2014 Aug 1.

PMID:
25088577
20.

Functional deregulation of KIT: link to mast cell proliferative diseases and other neoplasms.

Cruse G, Metcalfe DD, Olivera A.

Immunol Allergy Clin North Am. 2014 May;34(2):219-37. doi: 10.1016/j.iac.2014.01.002. Epub 2014 Mar 12. Review.

Supplemental Content

Support Center